Table 3.

Risks (%) of overdiagnosis among nonmetastatic prostate cancer patients diagnosed by prostate-specific antigen screening predicted by the fitted logistic regression model*

Gleason score	Age, y	PSA, ng/mL
		4.0–4.9	5.0–5.9	6.0–6.9	7.0–7.9	8.0–8.9	9.0–9.9
≤6	50–54	11.6	9.9	8.4	7.1	6.0	5.0
	55–59	19.5	16.8	14.4	12.3	10.5	8.9
	60–64	30.7	27.0	23.6	20.5	17.7	15.2
	65–69	44.9	40.4	36.1	32.1	28.2	24.7
	70–74	59.9	55.5	50.9	46.4	41.9	37.6
	75–79	73.3	69.6	65.6	61.4	57.0	52.5
	80–84	83.4	80.8	77.8	74.5	70.9	67.0
≥7	50–54	9.6	8.1	6.9	5.8	4.9	4.1
	55–59	16.3	14.0	11.9	10.1	8.6	7.3
	60–64	26.3	22.9	19.9	17.2	14.7	12.6
	65–69	39.6	35.3	31.3	27.5	24.1	20.9
	70–74	54.6	50.1	45.5	41.1	36.8	32.7
	75–79	68.8	64.8	60.6	56.1	51.6	47.1
	80–84	80.2	77.2	73.8	70.1	66.2	62.0

* PSA = prostate-specific antigen.